

Roche POC SARS-CoV-2 test gets EUA

September 2021—Roche announced that the FDA granted emergency use authorization for the Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System. The singleplex, RT-PCR test screens within 20 minutes both asymptomatic and symptomatic persons. The test, for point-of-care use, offers broad strain coverage of SARS-CoV-2 variants.

The Cobas SARS-CoV-2 Nucleic acid test is also available in markets that accept the CE mark.

[Roche](#), 800-428-5074